Hers vs Henry Meds: Which GLP-1 Medication You Receive

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics beneath them into decisions you can actually use. Explore the full Peptides & GLP-1 library.

What follows is independent editorial analysis. PlexusDx has no affiliate, sponsorship, or commercial relationship with Hers, Henry Meds, or their parent companies.

Full head-to-head: PlexusDx vs Henry Meds →

The "meds" in a Hers versus Henry Meds search is the real subject: people want to know what medication they will actually receive and how it is dispensed. So this page centers on the compound and the dispensing pathway rather than app design or marketing. Market context reflects April 2026.

What medication each program dispenses

Hers (Hims & Hers Health) runs subscription telehealth and, after a provider evaluation, dispenses either brand-name FDA-approved GLP-1 products or compounded semaglutide or tirzepatide through a licensed compounding pharmacy. Henry Meds pairs telehealth with a compounding-pharmacy pathway. The practical question for a "meds" search is which specific compound, at which dose, arrives at your door, and that is set at prescription time, not by the brand name on the box.

Brand-name versus compounded dispensing

The most consequential medication difference in this category is dispensing route. A brand-name FDA-approved product and a compounded preparation of the same active compound reach you through different pharmacy pathways, with different cost, packaging, and supply characteristics. Compounded semaglutide and tirzepatide are prepared by 503A compounding pharmacies. Both Hers and Henry Meds may use these routes, so confirm which applies to the specific medication you are prescribed.

The compounds themselves

Under either brand, the medications belong to the GLP-1 receptor agonist class. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety, and gastric emptying. The mechanism is a property of the molecule. Choosing Hers or Henry Meds selects a dispensing model and price, not a different pharmacology.

What the trials tested

The evidence attaches to the compound, not the pharmacy. Semaglutide for weight management was studied in STEP (NEJM 2021), tirzepatide in SURMOUNT (NEJM 2022), and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM 2024). Effect sizes depend on dose, compound, and population. Whichever brand prescribes it, the medication carries this same clinical record.

What the medication label never shows

No prescription captures your genetics. Variants in FTO, the fat-mass and obesity-associated gene, and in MC4R, GLP1R, and TCF7L2, describe the metabolic terrain the medication acts on. They are pathway-level markers and do not predict response to any specific compound. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2. Alongside the PlexusDx Weight Management Protocols, offered as Semaglutide Injection at $189 and Tirzepatide Injection at $289 month to month, it is the test before you invest approach: understand the biology the medication is entering before you fill the first prescription.

No affiliation: PlexusDx has no commercial relationship with Hers or Henry Meds and does not represent either company.

More from the Education Hub: GLP 1 Drugs and What Is GLP 1.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Hers or Henry Meds. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

What medications do Hers and Henry Meds actually prescribe?

Both prescribe GLP-1 receptor agonists after a provider evaluation. Depending on the program and your prescription, that may be a brand-name FDA-approved product or compounded semaglutide or tirzepatide from a licensed 503A pharmacy. The specific compound and dose are set at prescription time, so confirm what you are being given before you commit.

Is compounded medication different from the brand-name drug?

The active compound is the same class, but the dispensing route differs. Compounded semaglutide or tirzepatide is prepared by a 503A compounding pharmacy rather than sold as a brand product, which affects cost, packaging, and supply. It does not change the underlying mechanism, which the molecule itself determines.

Does the Precision Peptide Genetic Test tell me which medication to take?

No. It does not recommend or predict response to any specific medication. It maps pathway-level variants such as FTO, MC4R that describe your baseline GLP-1 and appetite biology, giving your provider upstream context to weigh alongside whichever compound and dispensing route you are considering.

Keep learning at the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.